Riskpilot← Back to searchSign inGet full accessNano Genetics Sweden AB
ABActiveOrg 5568537749Economic activity was not specified by tax authority · NACE 0000Est. 20110 employees
Revenue 2024
—
EBITDA margin
—
+4% vs 2023
Equity ratio
100.7%
Financial strength
Net profit 2024
SEK -7K
+1% vs 2023
| Revenue | — | — |
| EBITDA | SEK -6K | +4% |
| Net profit | SEK -7K | +1% |
| Total assets | SEK -11K | -227% |
| Equity | SEK -11K | -222% |
| Employees | 0 | — |
Legal name
Nano Genetics Sweden AB
Org number
5568537749
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
24 maj 2011
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-05-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva läkemedelsutveckling samt produktion av läkemedel och läkemedelssubstanser, konsultverksamhet inom läke- medel, import och export av läkemedel och medicinska artiklar, handel med fast egendom, värdepapper och finansiella instrument, verksamhet inom området DNA-diagnostik, konsult- och ut- vecklingsarbeten inom området teknologiska innovationer, verksamhet inom området nanoteknologi samt idka därmed förenlig verksamhet.
Address
Email
info@lbyggholding.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | — | — | — |
| Staff expenses | — | — | — | — | — |
| EBITDA | −6 | −5 | −12 | −6 | −6 |
| Depreciation & amort. | −2 | −1 | −1 | −1 | −1 |
| EBIT | −8 | −6 | −14 | −8 | −7 |
| Net financials | — | — | −0 | — | −0 |
| Profit before tax | −8 | −6 | −14 | −8 | −7 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −8 | −6 | −14 | −8 | −7 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 23 | 10 | 4 | −3 | −11 |
| Equity | 16 | 10 | 4 | −3 | −11 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 7 | 0 | 0 | 0 | 0 |
| Total debt | 7 | — | 0 | 0 | 0 |
EBITDA margin
-625000.0%
This company
15.8%
Market median
-3955796% vs market
20202024
Equity ratio
-1085100.0%
This company
38.2%
Market median
-2840676% vs market
20202024
Return on equity
-748600.0%
This company
18.4%
Market median
-4068578% vs market
20202024
Net profit margin
-748600.0%
This company
8.1%
Market median
-9242075% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-06-01 – 2024-05-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-06-01 – 2023-05-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-06-01 – 2022-05-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-06-01 – 2021-05-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-06-01 – 2020-05-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
DP Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Nano Genetics Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dariusz Przemyslaw Durzynski | Chief Executive Officer | 0 companies |
| Agnieszka Joanna Durzynska | Deputy Board Member | 0 companies |